Metastatic, hormone refractory prostate cancer: a randomised phase II study of the endothelin-a receptor antagonist atrasentan

European Urology Supplements ◽

10.1016/s1569-9056(02)80613-3 ◽

2002 ◽

Vol 1 (1) ◽

pp. 157 ◽

Author(s):

C. Schulman ◽

P. Abrahamsson ◽

R. Humerickhouse ◽

M. Weinberg ◽

J. Schmitt ◽

...

Keyword(s):

Prostate Cancer ◽

Receptor Antagonist ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Refractory

Download Full-text

The selective endothelin-a receptor antagonist improves quality of life (QOL) weighted time to progression in hormone refractory prostate cancer patients

European Journal of Cancer ◽

10.1016/s0959-8049(01)81300-9 ◽

2001 ◽

Vol 37 ◽

pp. S220 ◽

Author(s):

A. Singh ◽

R.J. Padley ◽

T. Ashraf

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Receptor Antagonist ◽

Cancer Patients ◽

Hormone Refractory Prostate Cancer ◽

Time To Progression ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Refractory

Download Full-text

A Phase II study of the safety, pharmacokinetics and efficacy of IncelTM (biricodar, VX-710) in combination with mitoxantrone (M) and prednisone (P) in advanced hormone refractory prostate cancer (HRPC)

European Journal of Cancer ◽

10.1016/s0959-8049(99)81827-9 ◽

1999 ◽

Vol 35 ◽

pp. S349 ◽

Author(s):

A. Einstein ◽

R. Lush ◽

R. Rago ◽

G. Bubley ◽

W.D. Henner ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory

Download Full-text

Docetaxel, Vinorelbine, and Zoledronic Acid as First-Line Treatment in Patients with Hormone Refractory Prostate Cancer: A Phase II Study

European Urology ◽

10.1016/j.eururo.2007.02.060 ◽

2007 ◽

Vol 52 (4) ◽

pp. 1020-1027 ◽

Author(s):

Giuseppe Di Lorenzo ◽

Riccardo Autorino ◽

Sisto Perdonà ◽

Michele De Laurentiis ◽

Massimo D'Armiento ◽

...

Keyword(s):

Prostate Cancer ◽

Zoledronic Acid ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Line Treatment ◽

Hormone Refractory ◽

First Line Treatment

Download Full-text

50 QUALITY OF LIFE IN A RANDOMIZED PLACEBO-CONTROLLED PHASE II TRIAL OF THE SPECIFIC ENDOTHELIN A RECEPTOR ANTAGONIST ZD4054 IN PAIN-FREE OR MILDLY SYMPTOMATIC PATIENTS WITH METASTATIC HORMONE-RESISTANT PROSTATE CANCER

European Urology Supplements ◽

10.1016/s1569-9056(09)60058-0 ◽

2009 ◽

Vol 8 (4) ◽

pp. 133 ◽

Author(s):

H. Payne ◽

C. Battersby ◽

S. Hughes ◽

M. Taboada ◽

N.D. James

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Receptor Antagonist ◽

Phase Ii ◽

Phase Ii Trial ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Resistant Prostate Cancer

Download Full-text

A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An illinois cancer center study

Cancer ◽

10.1002/1097-0142(19930915)72:6<1965::aid-cncr2820720629>3.0.co;2-x ◽

1993 ◽

Vol 72 (6) ◽

pp. 1965-1968 ◽

Author(s):

Timothy M. Kuzel ◽

Martin S. Tallman ◽

Daniel Shevrin ◽

Edward Braud ◽

Lary Kilton ◽

...

Keyword(s):

Prostate Cancer ◽

Continuous Infusion ◽

Phase Ii ◽

Phase Ii Study ◽

Cancer Center ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory ◽

Download Full-text

Hormone-refractory prostate cancer: overall survival improves using endothelin A receptor inhibitor

Oncology Times UK ◽

10.1097/01434893-200805000-00012 ◽

2008 ◽

Vol 5 (5) ◽

pp. 14

Author(s):

Rabiya S Tuma

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Hormone Refractory Prostate Cancer ◽

Endothelin A Receptor ◽

Endothelin A ◽

Hormone Refractory ◽

Receptor Inhibitor

Download Full-text

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC)

Investigational New Drugs ◽

10.1023/b:drug.0000047109.76766.84 ◽

2005 ◽

Vol 23 (1) ◽

pp. 79-84 ◽

Author(s):

Tahir Latif ◽

Laura Wood ◽

Cindy Connell ◽

David C. Smith ◽

David Vaughn ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory

Download Full-text

Phase II Study of Vinorelbine and Low-Dose Docetaxel in Chemotherapy-Naive Patients with Hormone-Refractory Prostate Cancer

The Cancer Journal ◽

10.1097/00130404-200307000-00011 ◽

2003 ◽

Vol 9 (4) ◽

pp. 286-292 ◽

Author(s):

Alan J. Koletsky ◽

Manuel L. Guerra ◽

Lori Kronish

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Low Dose ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory

Download Full-text

Phase II study of vlnorelbine in patients with hormone refractory prostate cancer

European Journal of Cancer ◽

10.1016/s0959-8049(97)84523-6 ◽

1997 ◽

Vol 33 ◽

pp. S33

Author(s):

A. Caty ◽

S. Oudard ◽

Y. Humblet ◽

M. Beauduin ◽

E. Suc ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Hormone Refractory

Download Full-text

899 PUBLICATION A phase II study of sequential chemotherapy with docetaxel-estramustine phosphate (DE) followed by mitoxantrone-prednisone (MP) in patients (pts.) with metastatic hormone refractory prostate cancer (MHRPC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81194-2 ◽

2005 ◽

Vol 3 (2) ◽

pp. 258

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Hormone Refractory Prostate Cancer ◽

Estramustine Phosphate ◽

Sequential Chemotherapy ◽

Hormone Refractory

Download Full-text